Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

[11] McDonald D(2005)Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 3403-94

[12] Simon TA(2009)The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 1136-1136

[13] Michaud K(2007)Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis Arthritis Rheum 56 1754-221

[14] Zhang C(2010)Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment Arthritis Res Ther 12 R67-215

[15] Shaw Y(2008)The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence Arthritis Rheum 58 919-767

[16] Shakley B(2011)Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data Pharmacoepidermiol Drug Saf 20 119-47

[17] Ferri L(2014)Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial Ann Rheum Dis 73 86-396

[18] Michaud K(2017)Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 76 1101-1997

[19] McDonald D(2010)Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss Ann N Y Acad Sci 1192 215-1826

[20] Doran MF(2008)Emerging therapeutics for rheumatoid arthritis Bull NYU Hosp Jt Dis 66 210-850

[11] McDonald D(2005)Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 3403-94

[12] Simon TA(2009)The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 1136-1136

[13] Michaud K(2007)Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis Arthritis Rheum 56 1754-221

[14] Zhang C(2010)Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment Arthritis Res Ther 12 R67-215

[15] Shaw Y(2008)The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence Arthritis Rheum 58 919-767

[16] Shakley B(2011)Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data Pharmacoepidermiol Drug Saf 20 119-47

[17] Ferri L(2014)Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial Ann Rheum Dis 73 86-396

[18] Michaud K(2017)Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 76 1101-1997

[19] McDonald D(2010)Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss Ann N Y Acad Sci 1192 215-1826

[20] Doran MF(2008)Emerging therapeutics for rheumatoid arthritis Bull NYU Hosp Jt Dis 66 210-850